Lantheus, Premier ink contract for Definity, Ablavar
Lantheus Medical Imaging and Premier Purchasing Partners have signed a three-year supplier contract for the Definity cardiac ultrasound contrast agent and Ablavar MR angiography blood pool imaging agent.
Definity is an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border cardiograms, North Billerica, Mass.-based Lantheus explained. Ablavar is an MR angiography contrast agent indicated to evaluate aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease.
Both agents will be offered to more than 2,500 hospitals nationwide and 76,000-plus healthcare sites.
Definity is an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border cardiograms, North Billerica, Mass.-based Lantheus explained. Ablavar is an MR angiography contrast agent indicated to evaluate aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease.
Both agents will be offered to more than 2,500 hospitals nationwide and 76,000-plus healthcare sites.